62 research outputs found
PORTRAIT OF A BJELOVAR PROFESSOR RUDOLF STROHAL
No full textRad se bavi životom i djelovanjem Rudolfa Strohala u Bjelovaru, u razdoblju od 1892. do 1895. godine. U prvome dijelu rada cilj autorica je bio predstaviti pedagoško djelovanje R. Strohala u bjelovarskoj gimnaziji, a u drugome dijelu upoznati čitatelje s njegovim stručnim i znanstvenim radom i objavljenim publikacijama. Članak se temelji na analizi arhivske građe, članaka iz lokalnog tjednika i tiskanih djela koja profesor Strohal u vrijeme svojih bjelovarskih godina potpisuje kao autor ili prevoditelj. Za potrebe istraživanja autorice su također koristile kritičke osvrte na njegove radove kao i relevantne rezultate historiografskih istraživanja. Sačuvana građa svjedoči da je Strohal dao izniman doprinos bjelovarskom školstvu na kraju 19. stoljeća. Budući da ova faza njegova djelovanja nije do sada bila predmet pomnijeg istraživanja, rad je i svojevrsni prilog razumijevanju Strohalova profesionalnog i životnog puta u cjelini.This paper focuses on the life and work of Rudolf Strohal in Bjelovar between 1892. and 1895. In the first part of the paper the goal of authors was to present Strohal’s pedagogic work in Bjelovar gymnasium (high school) and in the second part the goal was to familiarize readers with his professional and scientific work as well as with his publications. The paper relies on the analysis of archival material, articles from a local weekly newspaper and published works either authored or translated by professor Strohal in his years working in Bjelovar. For research purposes authors also used critical reviews of his work and relevant results of historiographic research. Preserved materials show that Rudolf Strohal made a significant contribution to educational work in Bjelovar at the end of the 19th century. Because this phase of his work has not yet been carefully analyzed, this work also contributes to better understanding of Strohal’s professional work and life as a whole
A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus
No full textBACKGROUND:Each individual psoriasis patient has different expectations and goals for biological treatment, which may differ from those of the clinician. As such, a patient-centred approach to treatment goals remains an unmet need in psoriasis.OBJECTIVE:The aim of this study was to review available data on patients' and physicians' decision criteria and expectations of biological treatment for moderate-to-severe psoriasis with the aim of developing a core set of questions for clinicians to ask patients routinely to understand what is important to them and thus better align physicians' and patients' expectations of treatment with biologics and its outcomes.METHODS:A literature search was conducted to identify key themes and data gaps. Aspects of treatment relevant when choosing a biological agent for an individual patient were identified and compared to an existing validated instrument. A series of questions aimed at helping the physician to identify the particular aspects of treatment that are recognised as important to individual psoriasis patients was developed.RESULTS:Key findings of the literature search were grouped under themes of adherence, decision-making, quality of life, patient/physician goals, communication, patient-reported outcomes, satisfaction and patient benefit index. Several aspects of treatment were identified as being relevant when choosing a biological agent for an individual patient. The questionnaire is devised in two parts. The first part asks questions about patients' experience of psoriasis and satisfaction with previous treatments. The second part aims to identify the treatment attributes patients consider to be important and may as such affect their preference for a particular biological treatment. The questionnaire results will allow the physician to understand the key factors that can be influenced by biological drug choice that are of importance to the patient. This information can be used be the physician in clinical decision making.CONCLUSION:The questionnaire has been developed to provide a new tool to better understand and align patients' and physicians' preferences and goals for biological treatment of psoriasis.© 2015 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology
Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence
No full textsi tratta di una revisone sistematica della letteratura sulla efficacia e profilo di sicurezza di etanercept nei pazieni con psoriasi moderata-sever
The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis
No full textPsoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2.2% of the population. The aetiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious and lifestyle factors. The manner in which genetic and environmental factors interact to contribute to the molecular disease mechanisms has remained elusive. However, the interleukin 23 (-23)/T-helper 17 (17) immune axis has been identified as a major immune pathway in psoriasis disease pathogenesis. Central to this pathway is the cytokine -23, a heterodimer composed of a p40 subunit also found in -12 and a p19 subunit exclusive to -23. -23 is important for maintaining 17 responses, and levels of -23 are elevated in psoriatic skin compared with non-lesional skin. A number of agents that specifically inhibit -23p19 are currently in development for the treatment of moderate-to-severe plaque psoriasis, with recent clinical trials demonstrating efficacy with a good safety and tolerability profile. These data support the role of this cytokine in the pathogenesis of psoriasis. A better understanding of the -23/17 immune axis is vital and will promote the development of additional targets for psoriasis and other inflammatory diseases that share similar genetic aetiology and pathogenetic pathways
Health Economic Aspects of Cold Plasma Therapy: Efficacy and Economic Application in the Treatment of Chronic Wounds using the Example of the Plasmajet kINPen((R)) MED
No full textWitte J, Gensorowsky D, Zeitler A, Greiner W, Strohal R. Gesundheitsökonomische Aspekte der Kaltplasmatherapie: exemplarische Betrachtung der Versorgung chronischer Wunden mithilfe des Plasmajet kINPen MED. Gesundheitsökonomie & Qualitätsmanagement . 2023.Hintergrund
Eine chronische Wunde wird als Integritätsverlust der Haut und darunter liegender Strukturen definiert, der trotz sachgerechter Therapie nicht innerhalb von sechs Wochen abheilt. Unabhängig von dieser zeitlichen Definition sollten Wunden, die auf eine chronische Erkrankung mit fortbestehender Ursache für Geschwürentwicklungen, die Ulzerationen, zurückzuführen sind, z. B. das Ulcus cruris arteriosum, das Ulcus cruris venosum oder das diabetische Fußsyndrom, als chronische Wunden angesehen werden [1] [2]. Die Ursachen für die Entstehung chronischer Wunden sind heterogen. Zu den weltweit häufigsten Formen chronischer Wunden zählen Unterschenkel-Ulzerationen (Ulcus cruris), das diabetische Fußsyndrom und der Dekubitus [2].
Nicht oder schlecht heilende Wunden können die Arbeitsfähigkeit, die körperliche Mobilität und den Allgemeinzustand von Menschen über Jahre mehr oder weniger stark einschränken und haben damit, aber auch aufgrund anderer Begleitumstände (z. B. Geruchsbildung und Wundsekretion) einen unmittelbaren Einfluss auf die Lebensqualität. Auch Narben können als späte Komplikation alle Bereiche der Lebensqualität in erheblichem Maße beeinträchtigen. Darüber hinaus stellen chronische Wunden ein Milieu für Keime dar, die über die lokale Ausbreitung hinaus über den Blutstrom auch zu einer Besiedlung des ganzen Körpers und zum Tod durch Sepsis führen können [3]. Neben den medizinischen Herausforderungen, die sich bei der Therapie chronischer Wunden stellen, können durch die lange andauernde Behandlung hohe Kosten für die Krankenversicherung sowie auch hohe gesellschaftliche Kosten durch Arbeitsunfähigkeit oder Frühberentung entstehen.
Geschätzt wird, dass in westlichen Industrienationen ca. 0,2% [4] bis 1% [2] der erwachsenen Bevölkerung unter einer chronischen Wunde leidet. Regionale Daten aus dem Jahr 2012 zeigen ebenfalls eine Prävalenz chronischer Wunden, definiert über eine Behandlung von mindestens acht Wochen, von 1,1% der deutschen Gesamtbevölkerung [5]. Die Prävalenz diabetischer Fußulzera wird mit 2% bis 10% der Patienten mit Diabetes berichtet [6]. Auch Angaben zu den Behandlungskosten sind mit hoher Unsicherheit verbunden und beruhen meist auf Studien mit geringer Fallzahl und eingegrenztem Patientenklientel. So wurden beispielsweise in einer Primärerhebung GKV-Behandlungskosten von durchschnittlich 7.600 Euro für Patienten mit Ulcus cruris pro Jahr berichtet [7].
Die Art der Durchführung einer Wundbehandlung hat eine sehr große Variationsbreite [6]. Ein allgemeingültiger und einheitlich definierter Standard existiert nicht [8] [9]. Seit einigen Jahren stehen jedoch auch moderne Formen der Wundbehandlung in Form von Kaltplasmatherapien zur Verfügung [1]. Im Juli 2021 ist der Gemeinsame Bundesausschuss (G-BA) im Rahmen einer sogenannten Potenzialbewertung auf Basis bislang verfügbarer Studien zu der Auffassung gelangt, dass die Kaltplasmatherapie bei chronischen Wunden das Potenzial einer Behandlungsalternative aufweist. Umfassende Bewertungen der ökonomischen Konsequenzen dieser Anwendungen liegen noch nicht vor. Auf Basis erster klinischer Anwendungsdaten auch aus dem deutschen Versorgungskontext lassen sich jedoch Hinweise zum Nutzen der Anwendung des Kaltplasmas in der Behandlung chronischer Wunden ableiten [10] [11]. Aus diesen Daten können zudem erste explorative Einblicke in die ökonomischen Aspekte der Kaltplasmatherapie gewonnen werden. Basierend auf den Grundlagen der gesundheitsökonomischen Bewertung neuer Gesundheitstechnologien diskutiert die vorliegende Arbeit die Daten zum klinischen und ökonomischen Nutzen der Jetplasmatherapie exemplarisch am Beispiel des Plasmajet kINPen MED
Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis
No full textBACKGROUND:Psoriatic arthritis (PsA) and co-morbidities of psoriasis represent a significant clinical and economic burden for patients with moderate-to-severe psoriasis. Often these co-morbidities may go unrecognized or undertreated. While published data are available on the incidence and impact of some of them, practical guidance for dermatologists on detection and management of these co-morbidities is lacking.OBJECTIVE:To prepare expert recommendations to improve the detection and management of common co-morbidities in patients with moderate-to-severe psoriasis.METHODS:A systematic literature review was conducted on some common co-morbidities of psoriasis-cardiovascular (CV) diseases (including obesity, hypertension, hyperglycaemia and dyslipidaemia), psychological co-morbidities (including depression, alcohol abuse and smoking) and PsA-to establish the incidence and impact of each. Data gaps were identified and a Delphi survey was carried out to obtain consensus on the detection and management of each co-morbidity. The expert panel members for the Delphi survey comprised 10 dermatologists with substantial clinical expertise in managing moderate-to-severe psoriasis patients, as well as a cardiologist and a psychologist (see appendix) with an interest in dermatology. Agreement was defined using a Likert scale of 1-7. Consensus regarding agreement for each statement was defined as ≥75% of respondents scoring either 1 (strongly agree) or 2 (agree).RESULTS:The expert panel members addressed several topics including screening, intervention, monitoring frequency, and the effects of anti-psoriatic treatment on each co-morbidity. Consensus was achieved on 12 statements out of 22 (3 relating to PsA, 4 relating to psychological factors, 5 relating to CV factors). The panel members felt that dermatologists have an important role in screening their psoriasis patients for PsA and in assessing them for psychological and CV co-morbidities. In most cases, however, patients should be referred for specialist management if other co-morbidities are detected.CONCLUSION:This article provides useful and practical guidance for the detection and management of common co-morbidities in patients with moderate-to-severe psoriasis
Zur theorie der willenserklärung,
No full text"Sonderdruck aus: Drei beiträge zum bürgerlichen recht. Heinrich Degenkolb zum funfzigjährigen doktorjubiläum im auftrag der Leipziger Juristenfakultät dargebracht von R. Sohm, E. Hölder, E. Strohal."Mode of access: Internet
Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis
No full textBACKGROUND
Psoriatic arthritis (PsA) and co-morbidities of psoriasis represent a significant clinical and economic burden for patients with moderate-to-severe psoriasis. Often these co-morbidities may go unrecognized or undertreated. While published data are available on the incidence and impact of some of them, practical guidance for dermatologists on detection and management of these co-morbidities is lacking.
OBJECTIVE
To prepare expert recommendations to improve the detection and management of common co-morbidities in patients with moderate-to-severe psoriasis.
METHODS
A systematic literature review was conducted on some common co-morbidities of psoriasis-cardiovascular (CV) diseases (including obesity, hypertension, hyperglycaemia and dyslipidaemia), psychological co-morbidities (including depression, alcohol abuse and smoking) and PsA-to establish the incidence and impact of each. Data gaps were identified and a Delphi survey was carried out to obtain consensus on the detection and management of each co-morbidity. The expert panel members for the Delphi survey comprised 10 dermatologists with substantial clinical expertise in managing moderate-to-severe psoriasis patients, as well as a cardiologist and a psychologist (see appendix) with an interest in dermatology. Agreement was defined using a Likert scale of 1-7. Consensus regarding agreement for each statement was defined as ≥75% of respondents scoring either 1 (strongly agree) or 2 (agree).
RESULTS
The expert panel members addressed several topics including screening, intervention, monitoring frequency, and the effects of anti-psoriatic treatment on each co-morbidity. Consensus was achieved on 12 statements out of 22 (3 relating to PsA, 4 relating to psychological factors, 5 relating to CV factors). The panel members felt that dermatologists have an important role in screening their psoriasis patients for PsA and in assessing them for psychological and CV co-morbidities. In most cases, however, patients should be referred for specialist management if other co-morbidities are detected.
CONCLUSION
This article provides useful and practical guidance for the detection and management of common co-morbidities in patients with moderate-to-severe psoriasis
29 March 2012 - Austrian Niederösterreich Governor E. Pröll with Klubobmann and Chairman of EBG MedAustron GmbH Council K. Schneeberger, Director General for Cultural Policy Amabssador M.Eichtinger and Permanent Representative of Austria to the UNO and Austrian Delegate to CERN Council Ambassador C. Strohal in the MedAustron facility at CERN building 184.
No full textCERN-HI-1203078 01 - 13: visit of LINAC 3 with M. Benedikt CERN-HI-1203078 14 - 20: in the Roy Billinge room CERN-HI-1203078 21- 22: visit of the LEIR accelerator in building 354 CERN-HI-1203078 23 - 55: signing the guest book with CERN Director-General R. Heuer and Head of International Relations F. Pauss CERN-HI-1203078 56 - 99: in building 184, Governor Pröll and CERN Director-General R. Heuer switch on the MedAustron ion source to produce the proton beam; visit MedAustron facility. CERN-HI-1203078 32:from left to right: Klubobmann and Chairman of EBG MedAustron GmbH Council K. Schneeberger; Director-General R. Heuer;Niederösterreich Governor E. Pröll;Head of International Relations F. Pauss;Permanent Representative of Austria to the UNO and Austrian Delegate to CERN Council Ambassador C. Strohal
Glagolitic manuscripts and charters in the Archives of Croatia
No full textGlagoljske rukopise koji se čuvaju u Arhivu Hrvatske u Zagrebu opisao je prvi put 1910. R. Strohal (Glagoljski spomenici u Kr. zemaljskom arhivu, Vjesnik kr. hrvatsko-slavonsko-dalmatinskoga Zemaljskog arhiva XII, 1910, 197-204). Od tada je u Arhiv Hrvatske prispjelo još glagoljskih rukopisa, a najviše u razdoblju od 1956 do 1960. kada su na temelju mirovnog ugovora iz 1947. iz Mađarske vraćene srednjovjekovne glagoljske isprave, koje su nekoliko puta prelazile iz Zagreba u Budimpeštu. Danas Arhiv Hrvatske ima dvadeset glagoljskih rukopisa i fragmenata i mnogo više glagoljskih isprava. Među rukopisima najvažniji je Dijalog Grgura pape iz 16. st. i fragment kalendara, za koji je autor utvrdio da pripada Prvom novljanskom brevijaru iz 1459.
Autor u uvodnom dijelu piše kako je nastala zbirka glagoljskih rukopisa u Arhivu Hrvatske, a zatim opisuje svaki rukopis i svaku ispravu. Za svaku ispravu donosi kratki sadržaj, signaturu i podatke o objavi, ako su isprave već objavljene. Za građu hrvatskoglagoljskog notarijata u Vrbniku i Dubašnici navodi samo godine iz kojih su notarski protokoli, koncepte ili izdane isprave te njihov broj.Glagolitic manuscripts and charters in the Archives of Croatia
The Glagolitic manuscripts that are kept in the Archives of Croatia were first described by R. Strohal in 1910 (Glagoljski spomenici u Kr. zemaljskom arkivu, Vjesnik kr. hrvatsko-slavonsko-dalmatinskoga Zemaljskog arhiva XII, 1910, 197-204). Since then more Glagolitic manuscripts have been obtained, particularly form 1956 to 1960. In that period the medieval Glagolitic charters, which had been transferred several times inbetween Zagreb and Budapest, were finally given back by Hungary on the basis of the 1947 peace agreement. Nowadays, the Archives of Croatia keep twenty manuscripts and fragments of books and many Glagolitic charters. The most famous manuscripts are the Dialogue of Pope Gregory (16th century) and the fragment of a calendar. The author of the paper has proved that the fragment belongs to the First Breviar of Novi Vinodolski in 1459.
In the introductory part the author explains the making of the collection of Glagolitic manuscripts. The introduction is followed by a detailed description of each manuscript and charter. There is a summary, reference number, and bibliographic items of publication (if there are any) for all charters. As for notarial documents of Vrbnik and Dubašnica written in Croatian and Glagolitic letters, the author gives the corresponding years of the registres, the first drapts or minutes, together with their number
- …
